Innovative use of molecular design technology is essential for discovering and developing new agricultural products at a faster pace. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences, LLC (NYSE: DOW), announced they have entered a new phase in their collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.
JBEI was selected as one of four DOE Bioenergy Research Centers (BRCs) to receive funding in support of innovative research on biofuels and bioproducts. JBEI receives additional support from the California Energy Commission, TeselaGen Biotechnology Inc., and the Heising-Simons Foundation.
TeselaGen has received a $500,000 matching grant to further develop its enterprise software platform for gene editing and engineering.
The In-Fusion Cloning Primer Design Tool, powered by TeselaGen, generates primer sequences and vector maps.
Using the power of nature in conjunction with advanced technology and informatics to produce and develop solutions for farmers is essential to advance agriculture. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced they have entered into a collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.
TeselaGen has received a $750,000 grant from the National Science Foundation to expand its computer aided design platform for building and modifying DNA with synthetic biology techniques. The Small Business Innovation Research Phase II grant will be used to further commercialize the “j5” technology under exclusive license from the Lawrence Berkeley National Laboratory.
Redbiotec and TeselaGen have announced a joint venture to build a scalable, integrated, rapid design and rapid prototyping infrastructure for the creation of a library for Herpesvirus vaccine development. This library will enable new concepts for vaccines against Herpesviruses and will enable the optimization and improvement of new and existing vaccine candidates.
Genomatica and TeselaGen have signed a multi-year agreement to license TeselaGen’s software, which uses synthetic biology approaches to build and modify DNA. The two companies also will work together to enhance TeselaGen’s software to meet Genomatica’s objectives.
By using TeselaGen’s technology, Genomatica expects to accelerate development of its proprietary organisms. These organisms are an important part of the overall process technology that Genomatica delivers to its licensees for the production of major chemicals from renewable feedstocks. TeselaGen’s software provides an advanced biological computer aided design and manufacture system, with automated DNA design and assembly protocol generation.
TeselaGen Biotechnology has secured a second National Science Foundation Small Business Innovation and Research grant to pursue “Directed DNA Synthesis and Assembly”. The grant is focused on the “Build” aspect of TeselaGen’s four-step approach to software for synthetic biology, encompassing a “Design, Build, Test, and Evolve” methodology.
TeselaGen Biotechnology has secured a National Science Foundation Small Business Innovation and Research grant to pursue “A Synthetic Biology Design-Build-Test Platform for Automated Combinatorial DNA Assembly”. The grant focuses on the first part of TeselaGen’s Design, Build, Test, Evolve approach to biomolecule design. According to TeselaGen CEO Michael Fero “We decided to put the design principles of Synthetic Biology to the test, building our software framework along lines that model the forward engineering approach, while not ignoring the special ability of biological systems to design themselves through evolutionary mechanisms”